Neo-Adjuvant Trials

1. Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy (ALMERA) Identifier: NCT02115464

ALMERA is a randomized, phase II, open label study in patients with locally advanced non-small cell lung cancer (NSCLC) which will compare standard radiotherapy plus concurrent chemotherapy versus the same treatment plus concurrent Metformin continuing for 12 months. Metformin is a well-tolerated and inexpensive drug that has the potential to improve cancer patient outcomes.
Juravinski Cancer Centre, Hamilton
Grand River Regional Cancer Centre, Kingston
Niagara Health System, St. Catharines

Montreal General Hospital, Montreal

Health Sciences Center, Winnipeg

Cross Cancer Institute, Edmonton

2. Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer Identifier: NCT02055170

The purpose of this study is to study the effect of hormone therapies (androgen pathway modification) on the outcomes of patients with lung cancer. This information may be of benefit for future treatment strategies, prevention and control.
Health Sciences Centre, Winnipeg